Scarica l'app Stockscreener
0.7974
1.43%
-0.0116
Precedente Chiudi:
$0.809
Aprire:
$0.82
Volume 24 ore:
183.22K
Relative Volume:
0.43
Capitalizzazione di mercato:
$6.95M
Reddito:
$3.95M
Utile/perdita netta:
$-14.59M
Rapporto P/E:
-0.6859
EPS:
-1.1626
Flusso di cassa netto:
$-14.46M
1 W Prestazione:
+3.87%
1M Prestazione:
-16.94%
6M Prestazione:
-37.21%
1 anno Prestazione:
-42.22%
Intervallo 1D:
$0.7699
$0.8408
Intervallo di 1 settimana:
$0.73
$0.85
Portata 52W:
$0.73
$2.42
Evogene Ltd Stock (EVGN) Company Profile
Compare EVGN vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
EVGN
Evogene Ltd
|
0.7974 | 6.95M | 3.95M | -14.59M | -14.46M | -1.1626 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.34 | 119.23B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.77 | 78.84B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
700.45 | 43.35B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.41 | 41.57B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.05 | 31.51B | 5.36B | 287.73M | 924.18M | 2.5229 |
Evogene Ltd Stock (EVGN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2021-10-08 | Iniziato | ROTH Capital | Buy |
| 2021-07-29 | Iniziato | Aegis Capital | Buy |
| 2020-12-01 | Iniziato | Cantor Fitzgerald | Overweight |
| 2013-12-16 | Iniziato | Oppenheimer | Outperform |
Evogene Ltd Borsa (EVGN) Ultime notizie
Evogene Ltd Stock (ISIN: IL0010831684) Faces Biotech Volatility Amid AI-Driven Crop Innovation Push - AD HOC NEWS
Evogene Ltd (EVGN) Q4 2025 Earnings Call Highlights: Strategic Shifts Amid Revenue Decline By GuruFocus - Investing.com Canada
Evogene (EVGN) Stock Analysis Report | Ratings, Financials & Performance - Benzinga Japan
Evogene outlines ChemPass AI-driven strategy and anticipates new collaborations amid organizational realignment - MSN
Evogene to Present Its Pharma Discovery Achievements at BIO-Europe Spring 2026 - Sahm
Evogene Ltd. (NASDAQ:EVGN) Q4 2025 Earnings Call Transcript - Insider Monkey
Evogene Earnings Call: AI Ambition Meets Cash Reality - The Globe and Mail
Evogene Financial Results: Quarterly and Annual ReportNews and Statistics - IndexBox
Evogene Ltd. Q4 2025 Earnings Call Summary - Yahoo Finance
Evogene: Q4 Earnings Snapshot - theheraldreview.com
Evogene earnings missed by $0.20, revenue topped estimates - Investing.com Australia
Evogene Q4 2025 Earnings Call Transcript - MarketBeat
Why Did EVGN Shares Drop More Than 14% Today? - Stocktwits
Earnings call transcript: Evogene’s Q4 2025 highlights restructuring gains - Investing.com
Earnings call transcript: Evogene’s Q4 2025 highlights restructuring gains By Investing.com - Investing.com India
Evogene Reports Fourth Quarter and Full Year 2025 Financial Results - Sahm
Evogene Reshapes AI-Driven Molecule Business With 2025 Results and Strategic Overhaul - TipRanks
EVOGENE ($EVGN) Releases Q4 2025 Earnings - Quiver Quantitative
Evogene Earnings Review: Q4 Summary - Benzinga
An Overview of Evogene's Earnings - Benzinga
Evogene Ltd expected to post a loss of 26 cents a shareEarnings Preview - TradingView
EVGN Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
EVGN Should I Buy - Intellectia AI
Is Evogene Ltd. stock heavily shortedJuly 2025 Retail & Reliable Trade Execution Plans - mfd.ru
Evogene refocuses on AI drug discovery platform ChemPass By Investing.com - Investing.com India
Evogene Details 2025 Strategic Refocus Around ChemPass AI and Core Health, Agriculture Markets - The Globe and Mail
Evogene refocuses on AI drug discovery platform ChemPass - Investing.com
Evogene Releases CEO Letter to Shareholders - Finviz
Evogene substantially completed divestment of non-core subsidiaries - marketscreener.com
Evogene (EVGN) pivots to ChemPass AI and core health and ag markets - Stock Titan
Fund Flows: Does Evogene Ltd have consistent dividend growth2025 Market WrapUp & AI Based Trade Execution Alerts - baoquankhu1.vn
Winners Losers: Is ProShares Trust ProShares UltraShort Consumer Staples likely to announce a buybackWeekly Stock Summary & Risk Adjusted Buy/Sell Alerts - baoquankhu1.vn
CEO Moves: Is Evogene Ltd in a consolidation phaseJuly 2025 PostEarnings & Expert-Curated Trade Recommendations - baoquankhu1.vn
Evogene Schedules Fourth Quarter and Full Year 2025 Financial Re - GuruFocus
Evogene Schedules Fourth Quarter and Full Year 2025 Financial Results Release – Company Announcement - Financial Times
Evogene sets March 5 date to reveal Q4 and full-year 2025 numbers - Stock Titan
Evogene and QUT partner on AI-based cancer therapies - Pharmaceutical Business review -
Ideas Watch: Is Huntington Ingalls Industries Inc a good stock for dollar cost averaging2025 Price Targets & Entry and Exit Point Strategies - baoquankhu1.vn
New AI-led push targets lung cancers that resist chemo and drugs - Stock Titan
Evogene and Queensland University of Technology (QUT) Announce a Collaboration to Advance AI-Driven Cancer Therapeutics - Nasdaq
Will Evogene Ltd. stock hit new highs in YEARBear Alert & Accurate Entry/Exit Alerts - mfd.ru
Why did EVGN shares drop more than 14% today? - MSN
What insider trading reveals about Evogene Ltd. stockMarket Sentiment Report & Fast Gaining Stock Reports - mfd.ru
Will Evogene Ltd. stock benefit from AI adoptionJuly 2025 Retail & Low Drawdown Momentum Ideas - mfd.ru
Evogene Ltd. Expands Google Cloud Collaboration to Integrate AI Agents into ChemPass AI™ - iGrow News
Evogene Secures $3.4 Million Through Warrant Inducement Deal - TipRanks
Evogene, Systasy and LMU University Hospital Munich Announce a Collaboration to Develop Novel Therapies for Neutrophil-Derived Inflammatory Diseases - Finviz
Evogene Ltd Azioni (EVGN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.48%
1.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):